A randomized controlled trial of inhaled corticosteroids (ICS) on markers of epithelial–mesenchymal transition (EMT) in large airway samples in COPD: an exploratory proof of concept study

This article was published in the following Dove Press journal:
International Journal of COPD
27 May 2014
Number of times this article has been viewed

Sukhwinder Singh Sohal1,*
Amir Soltani1,*
David Reid1,2
Chris Ward1,3
Karen E Wills1,4
H Konrad Muller1
Eugene Haydn Walters1

1National Health and Medical Research Council Centre of Research Excellence for Chronic Respiratory Disease, School of Medicine, University of Tasmania, Hobart, Tasmania, Australia; 2Iron Metabolism Laboratory, Queensland Institute of Medical Research, Brisbane, Queensland, Australia; 3Institute of Cellular Medicine, Newcastle University, Newcastle Upon Tyne, Tyne and Wear, UK; 4Department of Biostatistics, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia

*These authors contributed equally to this work

Background: We recently reported that epithelial–mesenchymal transition (EMT) is active in the airways in chronic obstructive pulmonary disease (COPD), suggesting presence of an active profibrotic and promalignant stroma. With no data available on potential treatment effects, we undertook a blinded analysis of inhaled corticosteroids (ICS) effects versus placebo on EMT markers in previously obtained endobronchial biopsies in COPD patients, as a “proof of concept” study.

Methods: Assessment of the effects of inhaled fluticasone propionate (FP; 500 µg twice daily for 6 months) versus placebo in 34 COPD patients (23 on fluticasone propionate and eleven on placebo). The end points were epidermal growth factor receptor (EGFR; marker of epithelial activation) and the biomarkers of EMT: reticular basement membrane (Rbm) fragmentation ("hallmark" structural marker), matrix metalloproteinase-9 (MMP-9) cell expression, and S100A4 expression in basal epithelial and Rbm cells (mesenchymal transition markers).

Results: Epithelial activation, “clefts/fragmentation” in the Rbm, and changes in the other biomarkers all regressed on ICS, at or close to conventional levels of statistical significance. From these data, we have been able to nominate primary and secondary end points and develop power calculations that would be applicable to a definitive prospective study.

Conclusion: Although only a pilot “proof of concept” study, this trial provided strong suggestive support for an anti-EMT effect of ICS in COPD airways. A larger and fully powered prospective study is now indicated as this issue is likely to be extremely important. Such studies may clarify the links between ICS use and better clinical outcomes and protection against lung cancer in COPD.

Keywords: pilot trial, reticular basement membrane, S100A4, EGFR, MMP-9, lung cancer

Background
Smoking-related chronic obstructive pulmonary disease (COPD) is the fourth most common cause of chronic disability and death in developed countries.1 Our limited insights into the details of airway remodeling in the airway wall in COPD mainly date from the 1960s, and our knowledge about the effects of inhaled corticosteroids (ICS) on such airway remodeling is scanty. This is especially true of data from endobronchial biopsies done in nonoperative volunteer patients, which contrasts with copious such studies on asthma.2

Correspondence: Eugene Haydn Walters
National Health and Medical Research Council Centre for Research Excellence in Chronic Respiratory Disease and School of Medicine, MS1, 17 Liverpool Street, Private Bag 23, Hobart, Tasmania, Australia
Tel +61 3 6226 4805
Fax +61 3 6226 7704
Email haydn.walters@utas.edu.au

© 2014 Sohal et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission.

International Journal of COPD downloaded from https://www.dovepress.com/ by 54.70.40.11 on 26-Apr-2020
For personal use only.
We have recently reported novel characteristics of airway remodeling in active smokers. These changes are especially marked in those with established COPD. The subepithelial reticular basement membrane (Rbm) was variably thickened but also markedly fragmented with clefts or elongated spaces within it, which is quite different from that in asthma (Figure 1), where the Rbm is homogeneously thickened and hyaline in appearance. These elongated clefts in the Rbm in COPD are usually not empty, but frequently contain cells. These cells positively express the mesenchymal markers S100A4 and vimentin, as well as matrix metalloproteinase-9 (MMP-9), and do not penetrate inflammatory or other immune cells. These changes are “classic” hallmarks of the process termed epithelial–mesenchymal transition (EMT), defined as the transition of epithelial cells to a mesenchymal phenotype with the potential to digest and migrate through the Rbm to the subepithelial lamina propria. The epithelium in COPD is also highly activated, with upregulation of epidermal growth factor receptor (EGFR). In general, these changes were most marked in currently smoking COPD subjects compared with ex-smoking COPD and physiologically normal smokers. We have also demonstrated hypervascularity in and around the Rbm, which would characterize the EMT in COPD as being Type III.

Vessel changes seemed much the same in both smoker groups (with COPD or not), and much less marked in ex-smoker COPD subjects, which suggests that vessel changes were mainly effects of smoking. Type III EMT is recognized as producing a highly dangerous pro-cancerous stroma immediately under the epithelium. Of course, we recognize that smoking, and especially COPD is closely related to lung cancer development, and such promalignant stroma has been described as being important in the development of other common epithelial malignancies. ICS have become standard treatment in severe COPD, on the basis of positive empirical results from large studies, demonstrating short-term improvement in lung function and longer term benefits in terms of quality of life, exacerbation rates, long-term physiological decline, and possibly mortality. Importantly, there are also reports about the effects of ICS on inflammatory stromal airway changes in COPD; there is also epidemiological and circumstantial evidence of a protective effect of ICS use against lung cancer development in the highly vulnerable COPD population.

To our knowledge, there have been no longitudinal trials published about the effects of ICS on EMT or other airway structural changes in COPD. In such a situation, the performance of a pilot trial has been advocated. Given published evidence linking EMT and epithelial cancers in general, and the potential effects of ICS on lung cancer risk, we believed that a pilot randomized trial evaluating the effects of ICS on EMT markers in COPD was warranted and so this “proof of concept” study was undertaken. This was a prospective analysis under blinded conditions that utilized tissue available from a previous study mainly directed at documenting changes in airway inflammatory cells, although it was always a stated intention to address airway remodeling at an appropriate time.

**Methods**

Using retrospectively obtained tissue, this study still constituted a prospective, double-blinded, randomized, and placebo-controlled study (Figure 2), but was intended as a pilot investigation given the paucity of data on the likely effects of ICS on the parameters of interest. A pilot study does not require a formal sample size calculation but is a precursor exercise to test whether the components of subsequent larger studies can work well together. Pilot studies provide valuable information such as that on patient recruitment and retention, the practicability of performing investigations, and an estimate of effect sizes, where no other information exists. The pilot study data may be analyzed as an “external pilot”, and it is understood that results from hypothesis testing should be treated as preliminary, with robust but pragmatic statistical management, and therefore, cautious interpretation. The details of the study design (full protocol available from the
authors) and data on inflammatory cell profiles have been published previously.17

Subjects
The demographics of the study groups are presented in Table 1. The study was approved by “The Human Research Ethics Committee (Tasmania) Network” and “The Alfred Health Human Ethics Committee” Melbourne (The Alfred Hospital), and is registered with the national trials registry (ANZCTR, Trial ID: ACTRN12612001111864). All subjects gave written, informed consent prior to participation. Details of subjects were published previously.17,22

Table 1 Demographics

<table>
<thead>
<tr>
<th>Groups (numbers)</th>
<th>FP (n=23)</th>
<th>Placebo (n=11)</th>
<th>Normal controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>61 (46–69)</td>
<td>61 (52–69)</td>
<td>44 (20–68)</td>
</tr>
<tr>
<td>Female/male</td>
<td>9/14</td>
<td>4/7</td>
<td>7/8</td>
</tr>
<tr>
<td>Current smoker/ex-smoker</td>
<td>13/10</td>
<td>4/7</td>
<td>N/A</td>
</tr>
<tr>
<td>Pack-year smoking history</td>
<td>44 (18–150)</td>
<td>51 (22–148)</td>
<td>N/A</td>
</tr>
<tr>
<td>GOLD stage II†</td>
<td>12/11</td>
<td>5/6</td>
<td>N/A</td>
</tr>
<tr>
<td>FEV1/FVC ratio</td>
<td>59 (41–68)</td>
<td>57 (38–68)</td>
<td>82 (71–88)</td>
</tr>
</tbody>
</table>

Notes: For personal use only.

Abbreviations: BD, bronchodilator; COPD, chronic obstructive pulmonary disease; FEV1, forced expired volume in 1 second; FP, fluticasone propionate; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; N/A, not available.
for research bronchoscopy over a number of years, and their endobronchial biopsies had been stored and then processed in the same way as for the longitudinal intervention subjects.\(^3\) Exclusion criteria include: 1) subjects with a history suggestive of asthma, which includes symptoms in childhood, related atopic disorders, eczema or hay fever, substantial day-to-day variability or prominent nocturnal symptoms, or a history of wheeze rather than progressive breathlessness, and any who had previously used ICS (oral or inhaled); 2) no major comorbidities such as uncontrolled diabetes, angina, or cardiac failure, nor other coexisting respiratory disorders including pulmonary fibrosis, lung cancer, or bronchiectasis, and subjects were not on medication; and 3) subjects who were unable to give written informed consent. Inclusion criteria include: 1) current-smokers with COPD aged 40–70 years with a smoking history equal to or more than 15 pack-years; subsequently obtained bronchoalveolar lavage (BAL) fluid had to be free of culturable bacteria; forced expiratory volume in 1 second (FEV1) 40%–80% predicted, with forced expiratory ratio (FER; ratio of FEV1 to forced vital capacity [FVC]) ≤ 70% post-bronchodilator with definite scalloping out of the descending limb of the flow–volume loop on spirometry. COPD in ex-smokers with 6 months of smoking cessation were included; and 2) normal healthy never smoking controls also underwent bronchoscopic examination and physiological evaluation. They were at least 18 years old with a FEV1/FVC ratio of 70% or higher and FEV1% predicted of 80% or higher; they had no history of respiratory illness.

**Bronchoscopy**
Bronchoscopy and endobronchial biopsies were performed in the standard way, as previously described.\(^2\)

**Immunostaining**
Tissue was processed as previously described.\(^3,4\) Following removal of paraffin, followed by hydration, sections were stained with these antibodies: monoclonal-anti-MMP-9 (R&D Systems, Inc., Minneapolis, MN, USA; MAB911; 1:50 for 2 hours), monoclonal-anti-EGFR (Chemicon S/A, São Paulo, Brazil; CBL417; 1:40 for 60 minutes), and anti-S100A4 polyclonal antibody (Dako, Glostrup, Denmark; A5114; 1:2,500 for 90 minutes). In each case, a non-immune immunoglobulin (IgG1 negative control (Dako; X0931 clone DAK-GO1) was performed to eliminate false positive staining and a positive tissue control (surgically resected lung tissue) was also used. Bound antibodies were elaborated using peroxidase-labeled EnVision™ + (Dako; K4001) and liquid dianaminobenzidine (DAB) + (Dako; K3468).

**Biopsy analysis**
Computer-assisted image analysis was performed with a Leica DM 2500 microscope (Leica Microsystems, Wetzlar, Germany), Spot insight 12 digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI, USA), and Image Pro (v5.1; Media Cybernetics, Inc., Rockville, MD, USA) software. All slides were coded and randomized by an independent person and then counted by a single experienced observer (SSS) blinded to the subject and diagnosis, with quality assurance on randomly selected slides provided by a clinical and academic pathologist (Professor Hans Konrad Muller; International Academy of Pathology and Royal College of Pathologists of Australasia, Sydney, Australia).\(^3,4\)

Quantification of indices was performed before and after treatments to compare the effects of interventions. Cellular staining changes in the basal epithelium and Rbm were documented. Cell numbers positive for S100A4 and MMP-9 and the number of vessels within the Rbm were normalized for purposes of comparisons relative to the total length of basement membrane assessed. EGFR was measured as a percentage of epithelium stained for EGFR over the total basement membrane length. Although the full picture of fragmentation of the Rbm includes linear “clefs” or elongated spaces/cracks in the Rbm, as fragments of Rbm commonly “hang off” and with similar pieces completely separated from the remainder (Figure 1), we have used Rbm linear splitting (ie, cleft formation) as a quantitative measure for the observation. Thus, the total length of splits was summed and normalized as a percentage of the length of Rbm. Normal control data were provided from physiologically normal, non-smoking, age-matched individuals, obtained previously in a published cross-sectional study.\(^3\)

**Statistical analyses**
At the time of developing this pilot investigation, there were no data on which to base power calculations. In keeping with the principles of such a pilot study, our analyses were predominantly exploratory by definition, with no formal sample size calculable. Recommendations for good practice are that where possible, approximately 20–30 patients at baseline should be evaluated, as in the present study, to investigate the distribution of outcomes of key study parameters.\(^21,23\) A limited set of hypotheses were tested, complementing descriptive data. We had one end point on epithelial activation, one on a structural change classically associated with EMT, and two putative mesenchymal biomarkers of EMT (S100A4 and MMP-9 expression, with the former analyzed separately in basal epithelium and Rbm cells).
The data subsequently reported were generally skewed, so results are presented as medians and ranges and non-parametric analyses of variance were performed. The effects of the interventions were assessed using Wilcoxon related-samples tests to compare the indices for each of the biomarkers before and after treatment within treatment groups and also as changes within the groups (active versus [vs] placebo). The differences between the indices for the placebo and ICS treatment groups after intervention and differences from normal controls were compared using the Mann–Whitney test. These statistical analyses were performed using SPSS (v15.0 for Windows; IBM Corporation, Armonk, NY, USA) with a two-tailed \( P \leq 0.05 \) considered statistically significant. In this exploratory analysis, no primary or secondary end points have been discriminated, and as regarded reasonable under the conditions of a pilot study, no statistical allowance was made for the potential problem of multiple and collinear comparisons.

**Sample size and power calculations, with putative primary and secondary outcomes**

From the data obtained, we estimated the sample size required for a definitive study that would include “full” statistical analysis of drug affect, including allowance for multiple comparisons. We prospectively specified a three-stage, fixed-sequence statistical testing procedure and adjusted “alpha” (power) for multiplicity accordingly. Firstly, we would specify EGFR expression in the epithelium as the primary “driving” outcome measure and test the null hypothesis of no difference using alpha =0.05. If the null hypothesis cannot be rejected there would be a rationale for no further testing. However, given the mechanistic uncertainty between EGFR upregulation and EMT, we have nominated a coprimary hypothesis related to the main descriptive structural hallmark of EMT, namely the aggregate lengths of splitting in the Rbm, so results are presented as medians and ranges and non-parametric analyses of variance were performed. The effects of the interventions were assessed using Wilcoxon related-samples tests to compare the indices for each of the biomarkers before and after treatment within treatment groups and also as changes within the groups (active versus [vs] placebo). The differences between the indices for the placebo and ICS treatment groups after intervention and differences from normal controls were compared using the Mann–Whitney test. These statistical analyses were performed using SPSS (v15.0 for Windows; IBM Corporation, Armonk, NY, USA) with a two-tailed \( P \leq 0.05 \) considered statistically significant. In this exploratory analysis, no primary or secondary end points have been discriminated, and as regarded reasonable under the conditions of a pilot study, no statistical allowance was made for the potential problem of multiple and collinear comparisons.

**Results**

Studying markers of EMT in airway biopsies proved practicable in a randomized trial setting. Recruitment, randomization and allocation concealment, 6 months of treatment, and assessments including two bronoscopies, were all practicable and acceptable to patients. The groups were reasonably well-matched for demographics and lung function (Table 1). All five pathological features of interest at baseline were significantly abnormal in COPD patients compared to normal controls.

**EGFR expression (as marker of activation) in the airway epithelium**

The percentage area of EGFR staining in the epithelium was statistically significantly lower after treatment for the ICS group (median [range]: 34% [14.6–59.5] before vs 5.8% [2.6–43.8] after; \( P<0.03 \) but not for the placebo group (14.4% [3.6–38.2] before vs 10.3% [1.3–39.1] after treatment; \( P=0.3 \); Figure 3). The active arm was essentially normalized after the ICS treatment (\( P=0.9 \) vs normal controls). There was modest evidence for aggregate change over time on ICS for EGFR relative to changes on placebo (\( P=0.06 \)), but with the removal of a single extreme outlier, this was statistically significant (\( P<0.03 \)).

**Fragmentation within the Rbm**

The lengths of splitting of the Rbm (length of splitting/total Rbm length \( \times 100 \)) was statistically significantly lower...
after treatment for the ICS group (median [range]: 19.2% [0.2–42.8] before vs 1.9% [0–29.2] after treatment; \( P < 0.03 \)) but not for the placebo group (24.0% [6.6–100] before vs 26.9% [2.5–48.5] after treatment; \( P = 0.4 \); Figure 4). Posttreatment, the active treatment arm had statistically significantly less splitting than the placebo group (\( P < 0.02 \); Figure 4), and Rbm splitting for the ICS group was not statistically significantly different from normal controls (\( P = 0.4 \)).

There was modest evidence for an effect of ICS on aggregate change in fragmentation relative to placebo (\( P = 0.06 \)), but again, after the removal of a single outlier, this was again statistically significant (\( P < 0.03 \)).

**S100A4 positive cells in the basal epithelium**

Cell staining (Figure 5) for S100A4 within the basal layers of the airway epithelium was statistically significantly lower after treatment for the ICS group (median [range]: 25.8 per mm [2.4–55.3] before vs 12.3 per mm [0.6–24.9] after; \( P < 0.004 \)) but not for the placebo group (19.8 per mm [2.9–31.6] before vs 17.4 per mm [10.3–35.5] after treatment; \( P = 0.4 \)). However, at the end of the treatment phase, the active arm was still showing statistically significantly higher numbers for S100A4 than for normal controls (\( P < 0.03 \)), ie, they were not fully normalized. Changes over time on ICS were also statistically significant compared to those on placebo (\( P < 0.009 \); Figure 5).

**S100A4 positive cells in the Rbm**

Cell numbers in the Rbm positive for S100A4 were statistically significantly fewer after treatment for the ICS group (median [range]: 44.4 per mm [15.3–92.6] before vs 20.8 per mm [2.6–60.7] after; \( P < 0.02 \)) but not on placebo (23.1 per mm [14–82.9] before vs 29.3 per mm [3.6–48.1] after treatment; \( P = 0.6 \); Figure 6). However, even after ICS, the cell numbers were still statistically significantly higher compared to normal controls (\( P < 0.004 \)), ie, they were not fully normalized. Aggregate individual changes on ICS were also statistically significantly greater than on placebo (\( P < 0.002 \); Figure 6).

**MMP-9 positive cells in the Rbm**

MMP-9 positive cells decreased statistically significantly in the Rbm in the treatment arm (median [range]: 0.5 per mm [0–4.3] before vs 0 per mm [0–0.6] after treatment; \( P < 0.02 \)) but did not change within the placebo group (1.1 per mm [0–4.1] before vs 1.3 per mm [0–2.7] after treatment; \( P = 0.8 \); Figure 7). After treatment, the active ICS treatment arm had statistically significantly fewer cells positive for MMP-9 in Rbm than did the placebo group (\( P < 0.05 \); Figure 7). Further, MMP-9 positive cell numbers in the active arm became quite
similar to normal control values after treatment ($P=0.3$). However, individual changes in MMP-9 expression over 6 months on ICS were not statistically significantly different to changes on placebo ($P=0.3$).

**Post hoc power calculations**

Based on our pilot data for 22 individuals, for the nominated primary outcome of change in EGFR, a total sample size of 36 (18 per balanced treatment group) would provide 80% power to detect the observed difference in mean change. This sample size would provide 65% power ($\alpha=0.05$) to detect the observed difference in Rbm splitting (for 80% power, 52 would be required), 97% power ($\alpha=0.0167$) for basal S100A4 (for 80% power, only 26 would be required), 48% power for Rbm S100A4, and 31% power for MMP-9. The sample sizes required to achieve 80% power for each of these secondary outcomes individually would be 26, 70, and 104 respectively, given the stringent conditions imposed by allowing for multiple comparisons (Table 2).

**Discussion**

We have previously shown that EMT is likely to be an active process in smokers’ airways, but is especially marked in current smokers with COPD. These findings were based on immunostaining for acknowledged “classic” empiric EMT markers and based especially on criteria for in vivo research on EMT as suggested by Zeisberg and Neilson. Recent papers by Milara et al and Wang et al have confirmed the potential for EMT as a major mechanism for small airway fibrosis (EMT Type II) in COPD. We have hypothesized that large airway EMT, which we have found is also associated with Rbm hypervascularity, may be important in both fibrosis and cancer pathogenesis and progression, as this is typical of what has been described as procancerous for epithelial tumors elsewhere. In this pilot randomized controlled trial, we have provided consistent but still provisional evidence that ICS over 6 months suppresses such EMT-related changes. We feel that the study was successful, at the very least, as a “proof of concept” study.

Our pilot trial indicated that intervention studies using bronchoscopic airway material for studying EMT in COPD are practicable, and we were able to provide reliable data regarding baseline levels and reproducibility of markers of EMT, as well as changes associated with ICS treatment, albeit in a pilot setting. For developing power calculations and sample size, we have now defined our primary end points as Rbm fragmentation (a classic structural hallmark of EMT) and epithelial activation, and the other downstream EMT...
Table 2 From the data obtained in the pilot study: observed mean and SD for changes in epithelial activation and EMT biomarkers for the placebo and ICS groups over 6 months of intervention and sample sizes required for 80% power for change for each end point in future potential studies (the secondary end points stringently share an α of 0.05)

<table>
<thead>
<tr>
<th>Marker</th>
<th>Placebo</th>
<th>ICS</th>
<th>Difference</th>
<th>N for 80% power: primary outcome</th>
<th>N for 80% power: joint secondary outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean</td>
<td>SD</td>
<td>N</td>
<td>Mean</td>
</tr>
<tr>
<td>EGFR*</td>
<td>7</td>
<td>-0.42</td>
<td>0.68</td>
<td>10</td>
<td>-1.32</td>
</tr>
<tr>
<td>Rbm splitting*</td>
<td>7</td>
<td>0.34</td>
<td>0.98</td>
<td>14</td>
<td>-2.19</td>
</tr>
<tr>
<td>Basal S100A4</td>
<td>7</td>
<td>2.65</td>
<td>13.1</td>
<td>14</td>
<td>-14.2</td>
</tr>
<tr>
<td>Rbm S100A4</td>
<td>8</td>
<td>-4.93</td>
<td>15.6</td>
<td>11</td>
<td>-20.1</td>
</tr>
<tr>
<td>MMP-9*</td>
<td>8</td>
<td>-0.03</td>
<td>5.44</td>
<td>11</td>
<td>-2.93</td>
</tr>
</tbody>
</table>

**Note:** *Calculated on log-transformed data.

**Abbreviations:** EGFR, epidermal growth factor receptor; EMT, epithelial–mesenchymal transition; ICS, inhaled corticosteroids; MMP-9, matrix metalloproteinase-9; Rbm, reticular basement membrane; SD, standard deviation.

Biomarkers of MMP-9 cell expression, in addition to S100A4 cell expression in the basal epithelium and Rbm, as secondary end points. The results of this analysis would suggest that if powering a study for these primary end points, then rather modest numbers are required. If S100A4 expression in the basal epithelium was treated as an independent variable, it would provide the most sensitive outcome, and perhaps a primary end point of combining S100A4 staining in both basal epithelial cells and Rbm together would be worth considering in numerically limited intervention studies.

The present study supports the concept that the epithelium in smokers/COPD is activated with high levels of EGFR expression. We nominated this as a primary outcome in the power calculations because it may well be that activation of the epithelium is a primary mechanistic event in inducing EMT and could also be important in cancer induction.

This pilot trial showed a reduction in EGFR expression in the airway epithelium in the active ICS arm compared to placebo, and again, it was essentially normalized. EGFR is overexpressed in many types of cancers, including non-small-cell lung cancer, and we have shown that this is highly expressed in the epithelium as part of the “COPD–EMT phenotype signal.” This is the first report of the effects of ICS on epithelial activation in COPD.

Taken together, these data provide strong suggestive evidence that fluticasone propionate could have significant anti-epithelial activation and anti-EMT effects in COPD, but is seemingly not able to completely eliminate all manifestations of EMT activity in COPD airways in all subjects over this 6-month timescale. We did not have sufficient numbers of samples to adequately address the question of whether current smoking status influences the effects of ICS on EMT markers; however, there was no obvious difference between these two groups in any of the biomarker changes on active treatment.

Given that this study was treated as a pilot for “proof of concept” and investigative power-determination purposes, with assumed insufficient numbers of participants to be a definitive study, we have avoided some statistical finesse, such as allowing for multiple comparisons, or treating primary versus secondary end points differently. Under such pilot circumstances, this is regarded as quite acceptable, but we have now provided evidence for how a larger definitive study could be designed.

The presence of COPD per se increases the risk of developing lung cancer by four- to fivefold when the smoking history is controlled for. Furthermore, up to 70% of lung cancer occurs in the context of mild-to-moderate COPD rather than end-stage. This implies that mechanisms specific to the relatively early pathogenesis of COPD may be involved in the development of lung cancer. Potential shared biological mechanisms in COPD and lung cancer include: chronic inflammation, matrix degradation, cell proliferation and apoptosis, abnormal wound repair, and angiogenesis. All of these are associated with EMT, especially EMT Type III, which is recognized as a promalignant condition in other situations of potential epithelial malignancy. Indeed, the relationship between COPD pathology and carcinogenesis may reflect a more general paradigm of epithelial instability and cancer etiology, bearing in mind that epithelial cancers make up 90% of all malignancies.

A number of observational studies in the literature have demonstrated that ICS reduce local and systemic inflammation among patients with COPD. ICS also improves lung function and the frequency of exacerbation in long-term users. Animal models of smoking-induced COPD have demonstrated that glucocorticoids strikingly inhibit the development of smoking-related lung cancer. In human epidemiological research, a US veterans cohort study of 10,474 patients in primary care clinics found that use of ICS, albeit only at high doses (as used in our study), was associated with appreciable (50%) decreased risk of lung cancer. Similar findings were reported in ex-smokers with COPD. However,
theTowards a Revolution in COPD Health (TORCH) study of ICS in severe COPD failed to show this effect, but it was not powered to pick this up, and was a study on severe rather than mild-to-moderate COPD, where lung cancer tends to occur in particular. TORCH would have excluded obvious lung cancer at entry and the study participants could be regarded as a survivor population. There is an essential need for both in vivo and in vitro human studies to understand the mechanistic link between COPD and airway cancer and how ICS and other drugs may affect it.8,9

Conclusion
This relatively small pilot study using retrospectively obtained tissue has actually provided quite strong suggestive evidence for an effect of ICS in downregulating epithelial activation and selected EMT biomarkers in COPD airways. We hope to have provided a strong stimulus for a larger confirmatory study, and have provided estimates of sample sizes needed for adequate power for appropriate statistical analyses. The numbers of COPD subjects needed to be recruited for such a study are quite feasible.

Disclosure
The authors report no conflicts of interest in this work.

References


